MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer

Zhang, Lifeng; Zhu, Ling; Zhang, Wei; Yuan, Wei; Song, Ninghong; Zuo, Li; Mi, Yuanyuan; Wang, Zengjun

doi:10.1186/s12881-019-0890-z

Cited by 7 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic polymorphisms of CXCR2 may influence the function of the protein by regulating gene expression. Several previous studies have investigated the correlation of CXCR2 mutations with risk of cancer [32][33][34][35][36][37][38]. However, the conclusions of these studies were not consistent.…”

Section: Discussionmentioning

confidence: 94%

“…Five genetic models were adopted to evaluate the overall ORs. For the CXCR2 C1208T polymorphism, the five models were allelic contrast (T allele vs. C allele), heterozygous comparison (TC vs. CC), homozygous model (TT vs. CC), dominant (TT+TC vs. CC), and recessive (TT vs. TC+CC) model [37,38]. A Q statistic test was used to calculate the heterogeneity among the included studies.…”

Section: Data Extraction Study Characteristics Were As Followsmentioning

confidence: 99%

See 1 more Smart Citation

Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility

Zhou

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Background. The CXC chemokines belong to a unique family of cytokines that participates in the progression and development of many malignant tumors. Evidence for the relationship between chemokine (C-X-C motif) receptor 2 (CXCR2) C1208T polymorphism and susceptibility to cancer remains inconsistent. Methods. Odds ratios (ORs), 95% confidence intervals (CIs), and combined analysis were used to investigate the effect of CXCR2 variation on cancer risk. Gene Set Enrichment Analysis (GSEA) and enzyme-linked immunosorbent assay (ELISA) were also used to evaluate the expression of CXCR2 in prostate cancer (PCA). Results. Across 11 case-control studies, 4,909 cases and 5,884 controls were involved in the current analysis. Individuals with a TT genotype were associated with increased risk of digestive cancer, compared to those with a TC+CC genotype ( OR = 1.16 , 95 % CI = 1.02 -1.31, P = 0.025 ). Individuals carrying the TT genotype had a 39% higher risk of urinary cancer than those carrying CC genotype ( OR = 1.39 , 95 % CI = 1.04 -1.87, P = 0.025 ). Individuals with a TT genotype showed a 56% augmented breast cancer risk, compared to those with a CC genotype ( OR = 1.56 , 95 % CI = 1.03 -2.35, P = 0.034 ). It was found that CXCR2 expression was downregulated in PCA. Compared with PCA subjects carrying the CC genotype, the expression of CXCR2 was decreased in patients with the TT genotype. Conclusions. The CXCR2 C1208T variation was associated with elevated risk of urinary, breast, and digestive cancer. However, the C1208T polymorphism was correlated with attenuated risk of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Data Extraction Study Characteristics Were As Followsmentioning

confidence: 99%

Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility

Zhou

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Further, this SNP was described to have a reduced risk for basal cell carcinoma (BCC) while exhibited no effect in squamous cell carcinoma (SCC) and melanoma ( 31 ). Conversely, a recent meta-analysis of several MMP8 polymorphisms showed that the K460T (rs35866072) and K87E (rs1940475) variants were not significantly associated with cancer susceptibility ( 32 ). Nevertheless, this SNP was not substantially studied despite its higher prevalence in PTCs of the Western population (80.6%) ( 8 ) and DTCs in our study (86%) suggesting that a future study with a large number of samples is warranted to discover the role of this SNP in thyroid cancer.…”

Section: Discussionmentioning

confidence: 99%

Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers

et al. 2021

View full text Add to dashboard Cite

Anaplastic lymphoma kinase (ALK), isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and matrix metalloproteinase 8 (MMP8) gene mutations have been frequently reported in human cancers; however, to the best of our knowledge, they have not been specifically examined in differentiated thyroid cancers (DTCs). Therefore, the present study aimed to determine the somatic mutational frequencies of these genes in DTCs. Mutational analysis of the ALK (exons 23, 24 and 25), IDH1 (exon 4), IDH2 (exon 4), and MMP8 (all exons 1-10) was performed in 126, 271, 271 and 50 DTCs, respectively. All the indicated exons were PCR-amplified and the PCR products were directly sequenced by Sanger sequencing. The present study identified a high frequency (86%; 43/50) of MMP8 single nucleotide polymorphism (SNP) and also found some rare SNPs of this gene (S3C, T32I, L310P and K460T) in DTCs but no somatic mutation in ALK, IDH1, IDH2 and MMP8. Analyses of 414 DTCs from The Cancer Genome Atlas revealed rare ALK (1%) and MMP8 (0.24%) mutations and none in IDH1 and IDH2. Conversely, analyses of 117 aggressive thyroid cancers [84, poorly differentiated thyroid cancer (PDTC); 33, anaplastic thyroid cancer (ATC)] from the Memorial Sloan Kettering Cancer Center cohort revealed ALK mutations in 3% of ATCs and fusions in 3.6% of PDTCs. IDH1 mutation was identified in 1.25% of PDTCs but not in ATC. IDH2 mutation was identified in 3% of ATCs but not in PDTC. The present study demonstrated that these genes are less frequently mutated in DTCs, but common in ATCs and PDTCs. It suggests that these genes serve a role in a small portion of DTCs and a more important role in ATCs and PDTCs and may serve as potential therapeutic targets in these subsets.

show abstract

“…Matrix metalloproteinase 8 ( MMP8 ) is largely secreted by neutrophils and malignant cells [ 9 ]. To date, the function of MMP8 in cancer progression has been confusing as various types of cancers demonstrated different prognosis outcome, despite presenting a similarly high level of MMP8 expression.…”

Section: Introductionmentioning

confidence: 99%

Lipofection of Single Guide RNA Targeting MMP8 Decreases Proliferation and Migration in Lung Adenocarcinoma Cells

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Matrix metalloproteinases (MMP) have been implicated as major determinants of tumour growth and metastasis, which are considered two of the main hallmarks of cancer. The interaction of MMP8 and other signalling molecules within and adjacent tumoral tissues, including immune cells, are rather elusive, particularly of adenocarcinoma cell type. In this study, we aimed to investigate the role of MMP8 in non-small cell lung cancer proliferation and invasiveness potential. Materials and Methods: We individually lipofected with two different single guide RNA (sgRNAs) that specifically targeted on MMP8, with CRISPR-Cas 9 protein into the cells. Results: Our results clearly indicated that the lipofection of these complexes could lead to reduced ability of A549 cells to survive and proliferate to form colonies. In addition, when compared to non-transfected cells, the experimental cell groups receiving sgRNAs demonstrated relatively decreased migration rate, hence, wider wound gaps in scratch assay. The quantitative real time-polymerase chain reaction (qRT-PCR) demonstrated significant reduction in the MAP-K, survivin and PI3-K gene expression. MMP8 might have protective roles over tumour growth and spread in our body. Conclusions: The delivery of sgRNAs targeting on the MMP8 gene could induce tumour cell death and arrest cell migratory activity.

show abstract

MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer

Cited by 7 publications

References 38 publications

Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility

Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility

Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers

Lipofection of Single Guide RNA Targeting MMP8 Decreases Proliferation and Migration in Lung Adenocarcinoma Cells

Contact Info

Product

Resources

About